IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 198 filers reported holding IMPAX LABORATORIES INC in Q4 2015. The put-call ratio across all filers is 0.81 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $1,061,000 | +12.0% | 54,530 | -4.2% | 0.01% | 0.0% |
| Q4 2017 | $947,000 | -18.2% | 56,895 | -0.3% | 0.01% | -28.6% |
| Q3 2017 | $1,158,000 | +30.1% | 57,071 | +3.2% | 0.01% | +40.0% |
| Q2 2017 | $890,000 | +143.2% | 55,286 | +91.2% | 0.01% | +66.7% |
| Q1 2017 | $366,000 | +57.1% | 28,920 | +64.6% | 0.00% | +50.0% |
| Q4 2016 | $233,000 | -33.4% | 17,570 | +18.9% | 0.00% | -33.3% |
| Q3 2016 | $350,000 | -0.3% | 14,776 | +21.4% | 0.00% | 0.0% |
| Q2 2016 | $351,000 | -22.2% | 12,168 | -13.5% | 0.00% | -25.0% |
| Q1 2016 | $451,000 | -15.9% | 14,071 | +12.3% | 0.00% | -20.0% |
| Q4 2015 | $536,000 | +44.1% | 12,534 | +18.6% | 0.01% | +25.0% |
| Q3 2015 | $372,000 | -22.8% | 10,571 | +0.8% | 0.00% | -20.0% |
| Q2 2015 | $482,000 | +5.7% | 10,489 | +7.7% | 0.01% | 0.0% |
| Q1 2015 | $456,000 | +92.4% | 9,738 | +29.9% | 0.01% | +66.7% |
| Q4 2014 | $237,000 | – | 7,495 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 423,161 | $13,406,000 | 7.47% |
| Aravt Global | 2,300,000 | $72,864,000 | 5.43% |
| Slate Path Capital LP | 2,330,000 | $73,814,000 | 5.16% |
| Orbimed Advisors | 6,678,000 | $211,559,000 | 2.02% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Iguana Healthcare Management, LLC | 100,000 | $3,168,000 | 1.53% |
| Penn Capital Management Company, LLC | 709,045 | $22,463,000 | 0.94% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 250,000 | $7,920,000 | 0.79% |
| NEW AMSTERDAM PARTNERS LLC/NY | 276,169 | $8,749,000 | 0.76% |
| Matarin Capital Management, LLC | 52,932 | $1,676,886,000 | 0.74% |